22nd Century Group Inc (XXII)

1.41
AMEX : Health Care
Prev Close 1.41
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.73 / 1.71
Avg Volume 918.20K
Exchange AMEX
Shares Outstanding 90.70M
Market Cap 131.51M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

World-Renowned Smoking Cessation Scientist, Dr. Michael Cummings, To Present Keynote Address At 22nd Century Annual Shareholder Meeting

World-Renowned Smoking Cessation Scientist, Dr. Michael Cummings, To Present Keynote Address At 22nd Century Annual Shareholder Meeting

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that K.

New Zealand Study Recommends 22nd Century's VLN Cigarettes As An Effective Tobacco Control Strategy

New Zealand Study Recommends 22nd Century's VLN Cigarettes As An Effective Tobacco Control Strategy

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the journal Nicotine and Tobacco Research has published a new...

Collect Smokin' Hot Profits From This Marijuana Biotech

Collect Smokin' Hot Profits From This Marijuana Biotech

This innovative biotech offers investors an intriguing play on the medical marijuana business.

22nd Century's

22nd Century's "Non- Or Minimally-Addictive" Cigarettes Gaining Support Of Leading Tobacco Scientists Around The World

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that leading scientists published more than 12 new studies involving...

22nd Century Invited To Speak At The Colorado Hemp Expo About The Company's Medical Marijuana Initiatives And Zero-THC Hemp Plants

22nd Century Invited To Speak At The Colorado Hemp Expo About The Company's Medical Marijuana Initiatives And Zero-THC Hemp Plants

22nd Century Group, Inc. (NYSE MKT: XXII), a leader in tobacco harm reduction and cannabis research, announced today that representatives of the Company's wholly-owned subsidiary, Botanical Genetics, have been invited to...

22nd Century Produces Zero THC Industrial Hemp At Anandia Labs

22nd Century Produces Zero THC Industrial Hemp At Anandia Labs

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company's research collaboration with strategic partner...

22nd Century Group Issues Annual Letter To Shareholders

22nd Century Group Issues Annual Letter To Shareholders

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company has issued the following letter to shareholders as...

22nd Century Group Files 2016 Annual Report And Announces Conference Call To Provide Business Update

22nd Century Group Files 2016 Annual Report And Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company filed its 2016 Annual Report on Form 10-K with the...

22nd Century Granted FDA Guidance Meeting For X-22 Smoking Cessation Aid

22nd Century Granted FDA Guidance Meeting For X-22 Smoking Cessation Aid

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on reducing the harm caused by smoking, announced today that the Company has been granted a guidance meeting with the Center for Drug...

22nd Century Provided With Written Feedback From FDA On The Company's Modified Risk Tobacco Product Application

22nd Century Provided With Written Feedback From FDA On The Company's Modified Risk Tobacco Product Application

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on reducing the harm caused by smoking, announced today that the Company has received written feedback from the Center for Tobacco...

Crede Dismisses Claims In Lawsuit Against 22nd Century

Crede Dismisses Claims In Lawsuit Against 22nd Century

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that Crede CG III, Ltd.

22nd Century Prevails Again In Frivolous Crede Lawsuit

22nd Century Prevails Again In Frivolous Crede Lawsuit

22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Company prevailed again in the most recent phase of the lawsuit filed by Crede CG...

FDA Provides Positive And Encouraging Feedback For 22nd Century's Very Low Nicotine MRTPA Filings

FDA Provides Positive And Encouraging Feedback For 22nd Century's Very Low Nicotine MRTPA Filings

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on reducing the harm caused by smoking, today announced that the U.

22nd Century Group Announces Major Scientific Collaboration With University Of Virginia

22nd Century Group Announces Major Scientific Collaboration With University Of Virginia

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Company has entered into a sponsored research agreement with the University of...

22nd Century To Present Overview Of Company's Medical Marijuana And Industrial Hemp Initiatives At LD Micro Investor Conference

22nd Century To Present Overview Of Company's Medical Marijuana And Industrial Hemp Initiatives At LD Micro Investor Conference

22nd Century Group, Inc. (NYSE MKT: XXII), a leader in tobacco harm reduction and cannabis research, announced today that the Company will present at the LD Micro Invitational Investor Conference at the Luxe Sunset...

22nd Century Group Files 2016 Third Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group Files 2016 Third Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today the Company's third quarter 2016 financial results and will provide a business update...

Former Santa Fe Natural Tobacco Company Executive Joins 22nd Century

Former Santa Fe Natural Tobacco Company Executive Joins 22nd Century

22nd Century Group, Inc. (NYSE MKT: XXII), a leader in tobacco harm reduction, announced today the hiring of Michael Zercher as the Company's Vice President of Business Development.

22nd Century's Very Low Nicotine Cigarettes Significantly Reduce Withdrawal And Craving Symptoms In Vulnerable Population Groups

22nd Century's Very Low Nicotine Cigarettes Significantly Reduce Withdrawal And Craving Symptoms In Vulnerable Population Groups

22nd Century Group, Inc. (NYSE MKT: XXII), a leader in tobacco harm reduction, announced today that scientists from the University of Vermont Center on Tobacco Regulatory Science, Brown University, Johns Hopkins University,...

22nd Century Group Announces Closing Of $11.4 Million Above-Market Registered Direct Offering

22nd Century Group Announces Closing Of $11.4 Million Above-Market Registered Direct Offering

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced that the Company closed today a registered direct stock offering with one existing institutional...

22nd Century Group Announces Above-Market Offering For $11.4 Million

22nd Century Group Announces Above-Market Offering For $11.4 Million

22nd Century Group, Inc. (NYSE MKT:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Company entered into an agreement, dated October 14, 2016, with one...

22nd Century Very Low Nicotine Cigarettes Could Reduce U.S. Smoking Rates By More Than 75%

22nd Century Very Low Nicotine Cigarettes Could Reduce U.S. Smoking Rates By More Than 75%

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that a group of leading scientists from the United States and New Zealand have published a...

Phase III Clinical Trial With 22nd Century's Very Low Nicotine Cigarettes Names Ten Major Research Institutions As Study Locations

Phase III Clinical Trial With 22nd Century's Very Low Nicotine Cigarettes Names Ten Major Research Institutions As Study Locations

22nd Century Group, Inc. (NYSE MKT:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that an update has been issued on the pivotal Phase III study entitled "Strategies...

22nd Century Announces Expiration Of 2,250,000 Crede Warrants

22nd Century Announces Expiration Of 2,250,000 Crede Warrants

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that warrants previously issued by the Company to Crede CG III, Ltd.

Overwhelming Physician And Consumer Support Cited For 22nd Century's

Overwhelming Physician And Consumer Support Cited For 22nd Century's "X-22" Very Low Nicotine Smoking Cessation Product

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced results from two separate independent surveys showing that strong consumer demand mirrors...

22nd Century Announces Expansion Of Cannabis Research Program

22nd Century Announces Expansion Of Cannabis Research Program

22nd Century Group, Inc. (NYSE MKT:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction and cannabis research, announced today that the Company's wholly-owned subsidiary, Botanical Genetics...

22nd Century Group Files 2016 Second Quarter Report Announces Conference Call To Provide Business Update

22nd Century Group Files 2016 Second Quarter Report Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is a leader in tobacco harm reduction, today released the Company's second quarter 2016 financial results and announced that it will provide a...

22nd Century Group Announces $5.0 Million Registered Direct Offering At Market

22nd Century Group Announces $5.0 Million Registered Direct Offering At Market

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Company entered into an agreement as of July 24, 2016 with one existing...

Nicotine Reduction Strategy Is Championed By Growing Number Of Scientists And Public Health Experts

Nicotine Reduction Strategy Is Championed By Growing Number Of Scientists And Public Health Experts

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that in this month's issue of Tobacco Control , Drs.